The endocannabinoid system as a novel approach for managing obesity

Related Experiment Video

Updated: Jul 12, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Joseph L Lillo1

  • 1Midwestern University/Arizona College of Osteopathic Medicine in Glendale, USA. jlillo3@cox.net

The Journal of the American Osteopathic Association
|September 6, 2007
PubMed

Insights

The endocannabinoid system influences appetite and metabolism. Rimonabant, a cannabinoid receptor 1 antagonist, effectively treats obesity and improves cardiometabolic risk factors.

Area of Science:

  • Endocrinology
  • Metabolic Science

Background:

  • The endocannabinoid system regulates food intake, metabolism, and energy storage.
  • Obesity is linked to significant cardiometabolic risk factors.

Purpose of the Study:

  • To evaluate the efficacy of rimonabant, a cannabinoid receptor 1 antagonist, in treating obesity and associated cardiometabolic risk factors.
  • To assess the long-term effects of rimonabant on weight, metabolic parameters, and inflammatory markers.

Main Methods:

  • Clinical trials comparing rimonabant to placebo in patients with obesity.
  • Assessment of body weight, waist circumference, insulin levels, glucose tolerance, lipid profiles, and inflammatory markers.
  • Evaluation of sustained efficacy over a 2-year period.

Main Results:

  • Rimonabant demonstrated statistically significant improvements in body weight, fasting insulin, glucose tolerance, HDL cholesterol, triglycerides, and waist circumference compared to placebo.
  • Significant reductions in inflammatory markers were observed with rimonabant treatment.
  • Sustained efficacy of rimonabant was noted for up to 2 years when combined with diet and exercise.

Conclusions:

  • Rimonabant offers a novel therapeutic strategy for managing obesity and related cardiometabolic risks.
  • The drug shows promise for long-term treatment due to sustained efficacy.
  • Rimonabant represents a significant advancement as a cannabinoid receptor 1 antagonist for obesity treatment.

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Related Concept Videos

Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...